Recent 8-K filings for CADL

• May 15, 2026 20:13 UTC other_material materiality 0.85 positive item 7.01item 9.01

  Candel reports 39% improvement in prostate cancer-specific DFS with aglatimagene in phase 3 extended follow-up

  Prostate cancer-specific DFS improved 39% vs placebo (HR 0.61, p=0.0031) at median 58-month follow-up.

• May 14, 2026 12:15 UTC earnings materiality 0.75 positive item 2.02item 9.01

  Candel Therapeutics Q1 2026 net loss $8.9M; BLA submission for CAN-2409 on track for Q4 2026

  Net loss of $8.9M in Q1 2026 vs net income $7.4M in Q1 2025; R&D expense $9.8M.

• Mar 12, 2026 23:59 UTC earnings materiality 0.70 neutral item 2.02item 9.01

  Candel reports Q4 2025 net loss of $29.5M; cash $119.7M; plans BLA for aglatimagene in Q4 2026

  Net loss Q4 2025: $29.5M vs $14.1M Q4 2024; full year net loss $38.2M vs $55.2M (2024).

• Feb 23, 2026 23:59 UTC other_material materiality 0.75 neutral item 1.01item 8.01item 9.01

  Candel Therapeutics prices $100M public offering of 18.3M shares at $5.45/share

  Gross proceeds $100M from 18,348,624 shares at $5.45; net ~$93.5M base, up to ~$107.6M if option exercised.

• Feb 19, 2026 23:59 UTC other_material materiality 0.75 positive item 1.01item 2.02item 8.01item 7.01item 9.01

  Candel secures $100M royalty funding from RTW for CAN-2409 prostate cancer launch; prelim cash $119.7M

  Candel enters $100M royalty funding deal with RTW; funds available upon FDA approval of CAN-2409 for localized prostate cancer.

• Nov 13, 2025 23:59 UTC earnings materiality 0.65 neutral item 2.02item 9.01

  Candel Q3 net loss $11.3M; cash $87M; secures $130M debt facility with Trinity Capital

  Net loss of $11.3M vs $10.6M in Q3 2024; R&D expenses $8.5M, G&A $4.7M.

• Oct 14, 2025 23:59 UTC other_material materiality 0.85 positive item 1.01item 2.02item 2.03item 3.02item 7.01item 8.01item 9.01

  Candel Therapeutics secures $130M loan; reports positive CAN-3110 survival data

  Entered $130M term loan facility with Trinity Capital; $50M drawn at closing, up to $80M additional subject to milestones.

• Aug 14, 2025 23:59 UTC earnings materiality 0.80 positive item 2.02item 9.01

  Candel Q2 net loss $4.8M vs $22.2M loss a year ago; positive phase 3 CAN-2409 results in prostate cancer

  Net loss of $4.8M in Q2 2025 vs $22.2M loss in Q2 2024; net other income of $6.4M due to change in warrant liability fair value.

• Jun 24, 2025 23:59 UTC other_material materiality 0.60 neutral item 1.01item 7.01item 9.01

  Candel Therapeutics raises $15M via registered direct offering of 3.2M shares at $4.67

  Gross proceeds ~$15M from sale of 3,221,395 shares at $4.67/share; closing expected June 25, 2025.

• May 28, 2025 23:59 UTC regulatory materiality 0.80 positive item 7.01item 8.01item 9.01

  FDA grants RMAT designation to Candel's CAN-2409 for prostate cancer; phase 3 met endpoint

  RMAT designation for CAN-2409 (aglatimagene besadenovec) in newly diagnosed localized intermediate-to-high-risk prostate cancer.

• May 22, 2025 23:59 UTC other_material materiality 0.75 positive item 7.01item 9.01

  Candel's CAN-2409 Phase 3 meets primary endpoint (p=0.0155) in localized prostate cancer; ASCO presentation June 3

  Statistically significant improvement in DFS (p=0.0155) with 30% risk reduction (HR 0.7) for CAN-2409 plus radiotherapy vs placebo plus radiotherapy.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.72 · Most common event other_material

7 positive 0 negative 9 neutral

source · CADL on sec.gov